# Judith Raimbourg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/judith-raimbourg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,757 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 20 |
| i10-index | 32 |
| Last Known Institution | Institut de Cancérologie de l'Ouest |
| OpenAlex ID | https://openalex.org/A5071502431 |
| ORCID iD | 0000-0003-2950-490X |
| Works | 189 |

## Researcher papers

- [Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/efficacy-and-safety-of-pembrolizumab-for-heavily-pretreated-patients-with/)
- [Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients](https://scholariq.org/papers/immune-checkpoint-inhibitors-associated-with-interstitial-lung-disease-in-cancer/)
- [First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/)
- [Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-anti-pd-1-antibody-pembrolizumab-in/)
- [Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-in/)
- [Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors](https://scholariq.org/papers/increased-frequency-of-anti-ma2-encephalitis-associated-with-immune-checkpoint/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion](https://scholariq.org/papers/ret-map-an-international-multicenter-study-on-clinicobiologic-features-and/)
- [A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers](https://scholariq.org/papers/a-phase-i-dose-escalation-study-of-oxaliplatin-delivered-via-a-laparoscopic/)
- [PFMG2025–integrating genomic medicine into the national healthcare system in France](https://scholariq.org/papers/pfmg2025-integrating-genomic-medicine-into-the-national-healthcare-system-in/)
- [Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer](https://scholariq.org/papers/patient-experience-of-medication-administration-and-development-of-a-patient/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Institut de Cancérologie de l'Ouest](https://scholariq.org/institutions/institut-de-cancerologie-de-l-ouest/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.